Life Biosciences Administers First Eye Injection to Reverse Aging in FDA Trial
Life Biosciences, a Boston-based company, has initiated a groundbreaking FDA trial by administering a cellular 'reprogramming' injection into the eye of a glaucoma patient. This experimental treatment, known as ER-100, aims to rejuvenate old cells to behave like young ones. The trial, which will include fewer than 20 participants across locations such as Boston, New York, Los Angeles, and Charleston, South Carolina, represents a significant step in anti-aging research. The injection uses three of the four 'Yamanaka factors,' proteins known for their cell reprogramming capabilities, while omitting the one most associated with cancer risk. The treatment is controlled by a daily doxycycline pill, allowing the process to be paused if safety concerns arise. This trial follows promising results in monkeys, where the treatment addressed vision loss. 
